Abstract
Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Current Drug Targets
Title: Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Volume: 10 Issue: 10
Author(s): Devalingam Mahalingam, Alain Mita, Kamalesh Sankhala, Ronan Swords, Kevin Kelly, Francis Giles and Monica M. Mita
Affiliation:
Keywords: Sarcoma, AKT, mTOR, IGF-1R, Ras, Apoptosis, VEGF and targeted therapy
Abstract: Sarcomas are a group of heterogeneous tumors that arise from mesenchymal tissue and account for approximately 1% of all adult solid malignancies diagnosed, although its incidence approaches 20% in pediatric cancers. Characterization of molecular abnormalities in patients with sarcomas, in particular the up-regulation of the receptor tyrosine kinase and the PI3K-AKT-mTOR pathway, loss or deletions of retinoblastoma (Rb) and p53 gene, increased VEGF expression and angiogenesis, dysregulation of apoptosis through Bcl-2 overexpression, along with oncogene mutations and activations, such as c-KIT in Gastrointestinal stromal tumors (GISTs), makes treatment with novel biological therapies a promising option. This review focuses on the molecular heterogeneity of soft tissue and bone sarcomas, novel biological therapies currently in clinical trials to target the various molecular pathways, and the potential biological agents in preclinical and early clinical development.
Export Options
About this article
Cite this article as:
Mahalingam Devalingam, Mita Alain, Sankhala Kamalesh, Swords Ronan, Kelly Kevin, Giles Francis and Mita M. Monica, Targeting Sarcomas: Novel Biological Agents and Future Perspectives, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577990
DOI https://dx.doi.org/10.2174/138945009789577990 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets [General Articles] Perspectives on Cancer Therapy: Cell Cycle Blockers and Perturbators
Current Medicinal Chemistry The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Currnt Status and a Dual Role of Physical Activity
Mini-Reviews in Medicinal Chemistry Applications of Nucleic Acid Drugs for Organ Transplantation
Current Topics in Medicinal Chemistry Peptide Aptamers: Specific Inhibitors of Protein Function
Current Molecular Medicine Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Hsp90: A Novel Target for Cancer Therapy
Current Topics in Medicinal Chemistry TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Current Topics in Medicinal Chemistry Adult Neurogenesis: Can Analysis of Cell Cycle Proteins Move Us “Beyond BrdU”?
Current Pharmaceutical Biotechnology Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets Withdrawal Notice: Emerging Biomarkers and Contributing Factors of Prostate Cancer
Current Cancer Therapy Reviews Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy
Current Diabetes Reviews Proteasomes as Drug Targets
Current Drug Targets Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets